TheraRadar
← Back
Data updated: Jun 28, 2026

POM PHARMA

Generics

POM PHARMA is a generic drug manufacturer focused on Ophthalmology, Neurology, Infectious Disease.

1995
Since
4
Drugs
-
Trials
0
New Drugs (2yr)

POM PHARMA's Key Drugs

POM PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

POM PHARMA's Recent FDA Approvals

New NDA/BLA approvals for POM PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

POM PHARMA's Therapeutic Areas

POM PHARMA's approved drugs and pipeline span 3 therapeutic areas, led by Ophthalmology and Neurology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Ophthalmology 33%
1 drugs
Neurology 33%
1 drugs
Infectious Disease 33%
1 drugs

POM PHARMA's Top Competitors

POM PHARMA's closest competitors by therapeutic-area and drug-target overlap include AbbVie, Pfizer, and Roche. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

POM PHARMA Pipeline Snapshot

Active clinical trials for POM PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Ophthalmology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling